StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Oncology Portfolio Total [legacy] — U.S. by Quarter

Oncology Portfolio Total [legacy] — U.S. ($M) ($M)

QuarterlyAnnual

Pfizer Oncology Portfolio Total [legacy] — U.S.: $3,327M in Q4 2025, up 9.0% from a year earlier. That is the highest of the 37 quarters on record here.

Latest, Q4 2025
3,327
Period ended Dec 31, 2025
Change on a year earlier
+9.0%
3,051 in Q4 2024
History
37 quarters
Since Q4 2016
Sources
33
Documents cited below

Where the Q4 2025 figure comes from

“|| Oncology | $ | 4,435 | $ | 4,064 | 9% | 8% | $ | 3,327 | $ | 3,051 | 9% | $ | 1,108 | $ | 1,012 | 9% | 7%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗

Reported in Form 8-K Revenue Tables.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOncology Portfolio Total [legacy] — U.S. ($M) ($M)Year on yearSource
Q4 2025Dec 31, 20253,327+9.0%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2025Sep 28, 20253,102+2.5%Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2025Jun 29, 20253,277+12.3%Form 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗
Q1 2025Mar 30, 20252,806+9.1%Form 8-K (Earnings / Guidance Release) (pfe-03302025xex99.htm, filed 2025-04-29) ↗
Q4 2024Dec 31, 20243,051+39.3%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2024Sep 29, 20243,026+43.3%Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2024Jun 30, 20242,918+34.7%Form 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗
Q1 2024Mar 31, 20242,572+29.7%Form 8-K (Earnings / Guidance Release) (pfe-03302025xex99.htm, filed 2025-04-29) ↗
Q4 2023Dec 31, 20232,190+8.7%Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
Q3 2023Oct 1, 20232,111+2.6%Form 8-K (Earnings / Guidance Release) (pfe-9292024xex99.htm, filed 2024-10-29) ↗
Q2 2023Jul 2, 20232,167+8.1%Form 8-K (Earnings / Guidance Release) (pfe-6302024xex99.htm, filed 2024-07-30) ↗
Q1 2023Apr 2, 20231,983+7.4%Form 8-K (Earnings / Guidance Release) (pfe-3312024xex99.htm, filed 2024-05-01) ↗
Q4 2022Dec 31, 20222,014-1.8%Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Q3 2022Oct 2, 20222,057+4.9%Form 8-K (Earnings / Guidance Release) (pfe-10012023xex99.htm, filed 2023-10-31) ↗
Q2 2022Jul 3, 20222,004+2.3%Form 8-K (Earnings / Guidance Release) (pfe-07022023xex99.htm, filed 2023-08-01) ↗
Q1 2022Apr 3, 20221,847+4.5%Form 8-K (Earnings / Guidance Release) (pfe-04022023xex99.htm, filed 2023-05-02) ↗

Cite this data

StockData. (2026). Pfizer Oncology Portfolio Total [legacy] — U.S. ($M), quarterly Q4 2016–Q4 2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/port-leg-onc-us

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.